SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tom pope6/18/2007 9:50:31 AM
   of 1826
 
ML:

MGI Pharma (MOGN, US$23.05, C-1-9)
Reiterate Buy; Raising PT to $28 from $25; Raise EPS estimates. Based on
newly released 3Q07 Medicare reimbursement rates, which increase doctor
profitability when using Aloxi vs. generic Zofran, we have greater confidence Aloxi
sales will rebound in 3Q. Since 4Q06, Aloxi has lost share to generic Zofran
because of a Medicare reimbursement anomaly that produced about a $42/dose
profitability benefit for docs that used generic Zofran instead of Aloxi to treat
chemo-induced nausea. But, beginning in 3Q07, we expect share to shift back to
Aloxi based on its revised $46/dose profitability benefit.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News